This finding indicates that patients with SRC GC who have larger tumors are at a higher risk of infiltrative growth, lymph node metastasis, and distant metastasis characterized by peritoneal dissemination, all of which are associated with a poor prognosis.[17–20] Neoadjuvant therapy should be administered regardless of the T and N staging because SRC GC has a distinct biological behavior, presents as a large-sized tumor (≥49 mm), and is associated with worse outcomes. Here, SRC is linked to metastatic malignant neoplasm in the lymph nodes.